Rea­ta sug­gests Friedre­ich's atax­ia pro­gram could be de­layed, send­ing stock plung­ing

Rea­ta Phar­ma­ceu­ti­cals $RE­TA made waves last Oc­to­ber when its drug omavelox­olone pro­duced pos­i­tive tri­al re­sults in treat­ing a rare neu­ro­log­i­cal dis­or­der, but the can­di­date …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER